{
    "clinical_study": {
        "@rank": "131296", 
        "arm_group": {
            "arm_group_label": "leuprorelin acetate", 
            "description": "Subcutaneous administration of leuprorelin acetate once every 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this survey is to examine the effect on QOL improvement and convenience of\n      switching to Leuprorelin acetate 3 moths depot 11.25 mg Injection Kit (Leuplin SR 11.25 mg\n      Injection Kit) from a 4-week adjuvant therapy with a LH-RHa 1 month depot over 48 weeks in\n      premenopausal breast cancer patients in daily medical practice. Influence of condition of\n      estrogen receptor expression on the efficacy and safety of Leuprorelin acetate SR 11.25 mg\n      Injection Kit was also evaluated."
        }, 
        "brief_title": "Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey: \"QOL Survey in Premenopausal Breast Cancer Patients\"", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This survey was designed to examine the effect on QOL improvement and convenience of\n      switching to Leuprorelin acetate 3 month depot 11.25 mg Injection Kit (Leuplin SR 11.25 mg\n      Injection Kit) from a 4-week adjuvant therapy with a LH-RHa 1 month depot over 48 weeks in\n      premenopausal breast cancer patients in daily medical practice, as well as to evaluate the\n      influence of condition of estrogen receptor expression  on the efficacy and safety of\n      Leuprorelin acetate SR 11.25 mg Injection Kit .\n\n      For adults, Leuprorelin acetate SR 11.25 mg Injection Kit (Leuplin SR 11.25 mg Injection\n      Kit) is usually administered subcutaneously once every 12 weeks. Prior to injection, the\n      plunger rod of the syringe is pushed upward with the needle pointed upward, allowing the\n      entire suspension fluid contained to be transferred to the powder. The powder is then fully\n      suspended in the fluid while ensuring that bubbles are not generated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Premenopausal breast cancer patients who meet all the following criteria are to be\n             enrolled in the surveillance:\n\n               1. Patients who received 4 weeks of treatment with a repository LH-RHa preparation\n                  within 1 week prior to administration of Leuplin SR 11.25 mg Injection Kit\n\n               2. Patients receiving Leuplin SR 11.25 mg Injection Kit as adjuvant therapy\n\n               3. Patients with performance status grade of 0 or 1\n\n               4. Patients who answered all of the questions on the \"QOL check sheet (I)\" at the\n                  start (Week 0) of treatment with Leuplin SR 11.25 mg Injection Kit\n\n        Exclusion Criteria:\n\n          -  Patients who meet any of the following criteria are to be excluded from the\n             surveillance:\n\n               1. Patients with a history of hypersensitivity to ingredient(s) in Leuplin SR 11.25\n                  mg Injection Kit or synthetic derivatives of LH-RH or LH-RH\n\n               2. Pregnant women, possibly pregnant women, and nursing mothers\n\n               3. Patients with advanced (T4 or M1 according to the TNM classification [General\n                  Rules for Clinical and Pathological Recording of Breast Cancer: 16th edition])\n                  or recurrent breast cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Breast cancer"
            }
        }, 
        "enrollment": {
            "#text": "2816", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134977", 
            "org_study_id": "265-211"
        }, 
        "intervention": {
            "arm_group_label": "leuprorelin acetate", 
            "description": "Leuprorelin acetate SR 11.25 mg Injection Kit", 
            "intervention_name": "Leuprorelin acetate", 
            "intervention_type": "Drug", 
            "other_name": "Leuplin SR 11.25 mg Injection Kit"
        }, 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 7, 2014", 
        "number_of_groups": "1", 
        "official_title": "Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: \"QOL Survey in Premenopausal Breast Cancer Patients\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "For the efficacy analysis set, the following parameters will be tabulated: changes in QOL (QOL-ACD score, QOL-ACD-B score, patient impression to switching medication) from baseline to 48 weeks of treatment will be tabulated.", 
            "measure": "Changes in QOL", 
            "safety_issue": "No", 
            "time_frame": "From baseline to 48 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134977"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of leuprorelin acetate whether or not it was considered related to treatment. Among these, events that are considered as having a causal relationship with leuprorelin acetate are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 48 weeks"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}